Dimerization of ABCG2 analysed by bimolecular fluorescence complementation by Haider, Ameena J. et al.
Dimerization of ABCG2 Analysed by Bimolecular
Fluorescence Complementation
Ameena J. Haider, Deborah Briggs, Tim J. Self, Hannah L. Chilvers, Nicholas D. Holliday, Ian D. Kerr*
School of Biomedical Sciences, University of Nottingham, Nottingham, United Kingdom
Abstract
ABCG2 is one of three human ATP binding cassette transporters that are functionally capable of exporting a diverse range of
substrates from cells. The physiological consequence of ABCG2 multidrug transport activity in leukaemia, and some solid
tumours is the acquisition of cancer multidrug resistance. ABCG2 has a primary structure that infers that a minimal
functional transporting unit would be a homodimer. Here we investigated the ability of a bimolecular fluorescence
complementation approach to examine ABCG2 dimers, and to probe the role of individual amino acid substitutions in dimer
formation. ABCG2 was tagged with fragments of venus fluorescent protein (vYFP), and this tagging did not perturb
trafficking or function. Co-expression of two proteins bearing N-terminal and C-terminal fragments of YFP resulted in their
association and detection of dimerization by fluorescence microscopy and flow cytometry. Point mutations in ABCG2 which
may affect dimer formation were examined for alterations in the magnitude of fluorescence complementation signal.
Bimolecular fluorescence complementation (BiFC) demonstrated specific ABCG2 dimer formation, but no changes in dimer
formation, resulting from single amino acid substitutions, were detected by BiFC analysis.
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Introduction
Resistance of cancers to a chemically broad spectrum of drugs is
referred to as multidrug resistance (MDR). Among the many
factors influencing MDR in humans are three members of the
ATP binding cassette (ABC) transporter family [1]. The ABCB1
(P-glycoprotein) and ABCC1 (multidrug resistance protein-1) are
both likely to act as monomeric proteins since they contain the
four domains expected of a canonical ABC transporter in a single,
long polypeptide [2]. For ABCG2 (breast cancer resistance
protein) the situation is more complicated – the cDNA encodes
a 655 amino acid protein comprising a single N-terminal
nucleotide binding domain (NBD) and a single C-terminal
transmembrane domain (TMD) [3]. Dimerization of ABCG2
would be the simplest form of a functional transporter, and the
protein forms a disulphide linked homodimer, but higher order
aggregation states have been identified (reviewed in [4,5].
The dimerization of ABCG2 is a critical step in its functional
transport capacity [6]. Dimerization of NBDs to form a closed
structure is a pre-requisite for ATP binding and hydrolysis, and
pharmacological evidence has demonstrated that these steps are
essential to drive affinity changes in the drug binding sites [7,8].
Therefore, understanding the dimerization of ABCG2 is impor-
tant for two reasons. Firstly, it will enable us to understand the
inter-domain communication in ABCG family transporters, which
are poorly understood presently [9], and which cannot be simply
modelled on the better understood ABCB family transporters from
mammals, and their bacterial homologues (see [1] for a
discussion). Secondly, the potential of agents that prevent ABCG2
dimerization as specific inhibitors of the pump offers an avenue
into drug discovery processes.
Previous studies of ABCG2 dimerization have had two principal
foci. The first has been on the cysteine residues in the extracellular
loop between predicted transmembrane (TM) helices 5 and 6
[10,11,12,13,14,15]. The three cysteines in this loop have all been
mutated individually, or together, and the results of these
investigations demonstrated that the protein contains a single
disulphide-linkage between C603 in each of two ABCG2 protomers
[13,14]. However, the disruption of this disulphide by mutation has
no functional effect on the protein [10,13,15]. The second series of
studies have aimed to identify, from bioinformatics analysis,
sequence motifs in the ABCG2 TM domains that might be
implicated in dimerization. For example, a GXXXG motif (where X
is any amino acid, and which is a common dimerization motif in TM
helices [16]) has been identified in predicted TM helix 1 but neither
this, nor a more extended motif has been shown to be necessary for
the formation of the ABCG2 dimer [17,18,19]. Additionally, a
conserved residue in TM5 of ABCG2 (G553) has been found to have
no role in the formation of the ABCG2 dimer [18].
In the current study we investigated whether the technique of
bimolecular fluorescence complementation (BiFC) can enable
insights into the ABCG2 dimer. The BiFC principle (Figure 1A) is
that interacting proteins tagged with molecular fragments of a b-
barrel fluorescent protein (YFP etc) enable the fragments of the
YFP to associate and refold, leading to the acquisition of a
fluorescent entity [20]. Typically, the N-terminal fragment
encodes the first 7-8 b-strands of YFP (including the tripeptide
that undergoes oxidation to generate the fluorophore), whilst the
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C-terminal fragment encodes the latter 3-4 b-strands [21,22].
Here, we show that ABCG2 was trafficked to the cell membrane
and functional when tagged N-terminally with half-molecules of a
variant form of YFP with efficient refolding kinetics (venus-YFP;
vYFP [23,24,25,26], and that co-expression of 2 ABCG2
constructs bearing complementing fragments of vYFP resulted in
gain of vYFP fluorescence. The sensitivity of this assay was
investigated by examination of ABCG2 isoforms containing point
mutations that are potentially involved in dimerization. No
significant differences in fluorescence complementation were
observed, leading to the suggestion that the single point mutations
engineered are not sufficiently altering the ABCG2 dimer to be
detected, or that the BiFC technique lacks the sensitivity to detect
any changes imparted by the mutations.
Methods
Cell culture and transfection
All tissue culture reagents were from Sigma, except for linear
polyethyleneimine (PEI, from Polysciences Inc). HEK293T cells
(ATCC code CRC-1573) were maintained in T75 flasks at 37uC/
5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM,
4500 mg/L glucose, L-glutamine, sodium pyruvate, and sodium
bicarbonate) supplemented with 10% (v/v) foetal calf serum and
100U/ml penicillin and 100 mg/ml streptomycin. Cells were
passaged at 80% confluence by trypsinization. Cells were seeded
24 hours prior to transfection on 6-well (26105 cells) or 96-well
(16104 cells), in reduced serum media (2-5% v/v). For
immunofluorescence, cells were seeded at a slightly lower density
onto poly-lysine coated glass cover slips in 6-well dishes. Cells were
transfected at approximately 50% confluence using linear PEI at a
PEI nitrogen : DNA phosphorus ratio of 10:1, by addition of
preformed PEI:DNA complexes to the growth media [27,28].
Twenty-four hours after transfection media was replaced by media
containing 10% v/v serum.
Construct generation
Molecular biology reagents were from New England Biolabs
unless stated. The construction of vectors encoding fragments of
vYFP has been described previously [21,23] and, in this study,
ABCG2 cDNA was incorporated into these vectors by conven-
tional restriction enzyme based cloning. ABCG2 cDNA was
amplified from a pre-existing vector containing an N-terminal
dodecahistidine tag, resulting in the removal of this affinity tag
(primers listed in Table 1). The constructs generated are depicted
schematically in Figure 1 and the following descriptors are used
throughout the manuscript; vYN refers to residues 2-173 (b-
strands 1–8) of venus YFP, vYC refers to residues 156–239 (b-
strands 8–11)of venus YFP, vYFP refers to entire venus YFP
[23,25] and eYFP is the entirety of enhanced YFP [29].
Point mutations in vYFP-ABCG2 plasmids were introduced
with pairs of oligonucleotide primers (Table 1) encoding the amino
acid substitution required. Reactions conditions were as above, but
contained 20 ng of template DNA, and PCR proceeded for 14–16
cycles. PCR products were treated with DpnI (10 units) by
incubation for one hour at 37uC before transformation into
chemically competent E. coli DH5a (Invitrogen). DNA sequencing
validated the fidelity of mutagenesis.
Figure 1. BiFC principle and ABCG2 BiFC constructs employed. A The underlying principle of BiFC is the refolding and maturation of a
chromophore (here vYFP) that occurs upon the interaction of two proteins (here shown as cylinders) bearing complementary fragments of the YFP
protein (red and blue interlocking shapes). B In the current manuscript, ABCG2 comprised of a N-terminal nucleotide binding domain (orange) and a
C-terminal TMD (olive green) is tagged with either full length YFP variants (yellow circles), or with complementing fragments of YFP variants, shown
as red and blue hemispheres. The tagging of YFP and fragments was at either the 59 (N-terminus) or the 39 (C-terminus) of the ABCG2 cDNA.
doi:10.1371/journal.pone.0025818.g001
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SDS-PAGE and western blotting
Cells were harvested by rinsing tissue culture plates twice with
ice-cold phosphate buffered saline (PBS) supplemented with 2 mM
EDTA and then collected by gentle pipetting into 1.5 ml tubes.
Cells were pelleted by centrifugation at 1000 g for 5 minutes,
resuspended in 250–500 ml of ice-cold PBS/2 mM EDTA
containing EDTA-free protease inhibitor cocktail set III (Calbio-
chem) and then lysed by sonication (2610 second bursts, 40%
output Microsonics Instruments). Protein concentration was
determined by a modified Lowry assay (Bio-Rad) and equal
quantities of protein were loaded onto 10% w/v polyacrylamide
gels as previously described. Protein gels were stained with
Coomassie stain (0.01% (w/v) Coomassie blue R250, 10% (v/v)
acetic acid, 40% (v/v) methanol) and de-stained in acetic acid/
methanol (both 10% v/v) overnight. For western blotting, proteins
were transferred onto nitrocellulose membrane (Amersham) by
electrophoresis in 25 mM Tris, 192 mM glycine. Membranes
were then incubated in a blocking solution, (5% skimmed milk
powder (w/v) in TBST (25 mM Tris, 0.15 M NaCl, pH 7.6, 0.1%
(v/v) Tween 20)) for one hour at room temperature. Membranes
were then incubated with primary antibody (BXP-21 (Calbio-
chem) at 1:2000 or anti-GFP (Roche) at 1:1000 dilutions) prepared
in the same blocking solution overnight at 4uC. After washing,
membranes were incubated in secondary antibody, (rabbit anti-
mouse horseradish peroxidase (DAKO) diluted at 1:2000 in
blocking solution) for 1 hour at room temperature. The mem-
branes were then washed and developed using Enhanced
Chemiluminescence, ECL (Supersignal West Pico; Thermo
Scientific).
Flow cytometry
Transiently transfected HEK293T cells were analysed by flow
cytometry for both protein expression and protein function in
accordance with previous protocols [30]. Cells were washed twice
then harvested in sterile, ice-cold PBS and collected into 15 ml
Falcon tubes. Cells were pelleted by centrifugation at 150 g for
5 min at 4uC then washed with ice-cold PBS and re-centrifuged.
Pellets were resuspended in flow cytometry buffer (1% (v/v) foetal
calf serum in phenol red-free DMEM) and aliquotted into facs
tubes as 100 ml aliquots at a cell density of 1–26107 cells per ml.
For detection of cell surface ABCG2 expression, transfected
HEK293T cells were incubated with 1:100 dilution of a
phycoerythrin (PE; lEX 546 nm; lEM 578 nm) conjugated
monoclonal antibody (5D3; R&D systems). An isotype control
antibody IgG-PE (Abcam) was employed in parallel experiments
to validate the specificity of 5D3 binding. For analysis of function,
cells were incubated with mitoxantrone (lEX 635 nm; lEM
670 nm; 5 mM; Sigma) in the presence or absence of fumitre-
morgin C (FTC, a gift of the NIH, Maryland; 1–5 mM).
Substrates and inhibitors were added from DMSO stocks so that
the final solvent concentration was below 0.5% v/v. After 30
minutes incubation at 37uC with occasional inversion cells were
pelleted by centrifugation, washed twice with ice-cold flow
cytometry buffer and finally resuspended in 300–400 ml of flow
cytometry buffer. The tubes were then analysed by Beckman-
Coulter XL-MCL Flow cytometer. Flow cytometry data were
analysed using WEASEL v.2 (The Walter and Eliza Hall Institute
of Medical Research). Cells were gated using forward scatter (FS)
and side scatter (SS) to exclude dead cells, cellular debris etc.
Gated cells were then quantified as histograms representing the
number of cell events with a particular fluorescence.
Immunofluorescence
HEK293T cells transfected with required constructs were fixed
on cover slips with 4% (w/v) paraformaldehyde (PFA) in PBS for a
maximum of 5 minutes at room temperature before being washed
twice with PBS and incubated in 3% (w/v) BSA in PBS (blocking
solution) for one hour at room temperature. For cells that need
permeabilization (to allow entry of an antibody that recognizes an
intracellular epitope, e.g. BXP-21) a 5 minute incubation in 0.05%
(v/v) TritonX-100 in PBS was included before the blocking step.
Following blocking, cells were incubated for 1 hour with primary
antibody (BXP-21; Calbiochem, or 5D3; Millipore) prepared at
1:2000 dilution in incubation buffer (0.3% w/v BSA in PBS). The
primary antibody solution was removed and the cells were washed
thrice with incubation buffer. Cells were then incubated in
secondary antibody (goat anti-mouse monoclonal antibody
conjugated to AlexaFluor 488 green fluorescent dye; Invitrogen),
at a 1:1000 dilution in incubation buffer. Cells were then washed
thrice with incubation buffer and then mounted onto microscopic
slides with 20–40 ml of Vectashield Mounting Medium with DAPI
(Vector labs).
Confocal microscopy
Greiner Bio-one ‘mclear’ black-sided 96-well plates (655090)
were coated with poly-L-lysine for an hour at room temperature,
before seeding HEK293T cells at a density of 1.0–1.56104 cells
per 100 ml of medium per well. Cells were transiently transfected,
as described earlier, and 48 hours subsequently, cells were washed
twice with sterile HEPES buffered saline (HBS) and then
maintained in HBS with membrane permeant Hoechst 33342
dye (0.4 mM) added to stain nuclei before being analysed on an
ImageXpress Micro imaging system, using a Nikon 40x NA 0.6
Extra Long Working Distance objective (Molecular Devices, Inc.
Table 1. Oligonucleotide primers employed.
Primer Sequence 59-39 Restriction site Purpose
EYFPG2F CCTGTATTTTCAGGAATTCTATGTCTTCCAG EcoRI Generation of ABCG2 tagged N-terminally with complete eYFP
YFPG2R GCTTGGTACCGATCTAGAATCCAATTTAAGAATA XbaI Common reverse primer for tagging ABCG2 N-terminally with
fragments of vYFP or with complete eYFP
VYFPG2F CCTGTATTTTCAGGAATTCATGTCTTCCAG EcoRI Generation of ABCG2 tagged N-terminally with vYFP fragments
G2YFPF CCTGTATTTTCAGGGATCCATGTCTTCCAG BamHI Generation of ABCG2 with C-terminal vYFP fragments
G2YFPR GAGCTCGGATCCCTCGAGAGAATATTTTTTAAG XhoI Generation of ABCG2 with C-terminal vYFP fragments
E211QF ATCTTGTTCTTGGATCAACCTACAACAGGCTTAGACTCAAG n/a Mutating E211Q
C603AF ACAGGAAACAATCCGGCCAACTATGCAACATGTACT n/a Mutating C603A
doi:10.1371/journal.pone.0025818.t001
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USA, [23]). Cells were imaged (9 sites/well) using the following
excitation (lex) and emission (lem) filter sets to detect (i) Hoechst
33342 lex 377 nm (bandpass; BP 50 nm) and lem 447 nm (BP
60 nm) and (ii) YFP BiFC, lex 482 nm (BP 35 nm) and lem
536 nm (BP 40 nm). An automated cell scoring algorithm applied
to each image (MetaXpress 2.0, Molecular Devices) identified the
total number of cells by nuclear count (Hoescht staining), and the
percentage of BiFC ‘‘positive’’ cells, based on a manual minimum
threshold for average cytoplasmic intensity of YFP BiFC
fluorescence (set with reference to positive/negative plate controls).
The individual cell data was then filtered by AcuityXpress 1.0
(Molecular Devices) to obtain the average cytoplasmic BiFC
intensity for the ‘‘positive’’ transfected population. Typically,
several thousand cells were identified and quantified for each
condition in each independent experiment.
Statistical analysis
Data were analyzed with Prism5 (Graph Pad) and/or Microsoft
Excel, using ANOVA and Student’s t-tests, with P-values of less
than 0.05 being considered significant for any set of data.
Results and Discussion
N-terminal but not C-terminal tagging of ABCG2 with
YFP fragments supports protein localization and function
The dimerization of ABCG2 was investigated using bimolec-
ular fluorescence complementation, a protein:protein interaction
technique that relies on the ability of molecular fragments of
YFP to re-associate and refold into a fluorescent structure
(Figure 1A [31]). Here we employed the vYFP isoform as its
BiFC fragments can refold at 37uC with fast folding kinetics
[22,23,24,26]. ABCG2 has both its N-terminus and its C-
terminus exposed to the intracellular surface [32] and thus 6
constructs were required for use in this study (Figure 1B). Two of
these, YFP-ABCG2 and ABCG2-YFP, are controls in which the
full length YFP is tagged to the N- or C-terminus respectively of
ABCG2. For convenience in these control constructs, the N-
terminal full length construct employed was eYFP, rather than
vYFP. The other 4 constructs represent proteins in which
residues 2–173 (vYN) and residues 156–239 (vYC) are tagged to
the N-terminus of ABCG2, and the same two fragments fused to
the C-terminus of ABCG2. All constructs are shown diagram-
matically in Figure 1B, and the associated nomenclature is also
given in this figure.
All constructs were examined for expression following transient
transfection of single constructs into HEK293T cells and, using
polyethyleneimine (PEI) as the transfection reagent [27], the
percentage transfection efficiency was routinely greater than 50%,
in accordance with previous results on other ABC proteins
expressed in HE293T cells [33]. To validate the cell surface
expression of ABCG2 isoforms carrying vYFP fragments at the N-
terminus we performed immunofluorescence on fixed, but
unpermeabilized cells with the monoclonal antibody 5D3, which
recognizes an extracellular epitope ([34], Figure 2A). Parallel flow
cytometry with the same antibody again revealed the surface
expression of ABCG2 and confirmed the high percentage
transfection efficiency. Western blotting under denaturing condi-
tions using the BXP-21 antibody [35] revealed the presence of
proteins with the expected molecular weights (vYN-ABCG2 at
approximately 90 kDa; and vYC-ABCG2 at approximately 80
Figure 2. N-terminal tagging with K YFP molecules does not
affect expression and targeting of the ABCG2 protein to the
plasma membrane. A HEK293T cells were transfected as described
and 48 hours later were fixed and incubated with monoclonal 5D3
antibody directed towards an extracellular epitope in ABCG2, and a
secondary antibody coupled to AlexaFluor 488, before being counter-
stained with DAPI and mounted for fluorescence microscopy. Top
panels show the presence of ABCG2 at the plasma membrane, and the
lower panel is a merged image of the 5D3 and DAPI. B Cells were
transfected and analysed by flow cytometry as described following
incubation with phycoerythrin (PE) conjugated control antibody (IgG-
PE; green filled distribution) or PE-conjugated 5D3 (unfilled distribution)
which recognizes an extracellular epitope of ABCG2 In A and B the left
hand column represents ABCG2 tagged N-terminally with vYN (residues
2–173 of vYFP), the right hand panel represents ABCG2 tagged N-
terminally with vYC (residues 156–239 of vYFP). Scale bars are 10 mm,
and the data are representative of at least 4 independent transfections.
C Cells were transfected and 20 mg of whole cell lysate was analysed by
SDS-PAGE and western blotting, using BXP-21 to identify ABCG2 fusion
proteins. The expression level of the three constructs is comparable. A
number of lower molecular weight breakdown products were observed
for the fusion with the C-terminus of vYFP, although the extent of this
was variable. A parallel Coomassie stained gel was employed to verify
equal protein loading (data not shown).
doi:10.1371/journal.pone.0025818.g002
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kDa), with evidence of lower molecular weight breakdown
products, presumably reflecting the increased protease sensitivity
of ABCG2 when tagged with partially unfolded protein fragments
of vYFP (as discussed at length in [26]).
The effect of tagging ABCG2 at the N-terminus has been
previously investigated with poly-histidine [8,36] and full length
green fluorescent protein [6] and in both cases the tagged protein
retained function. However, the effect of tagging with fragments of
YFP has not previously been described. We examined the ability
of vYN-ABCG2 and vYC-ABCG2 to export mitoxantrone in
transiently transfected cells using flow cytometry (Figure 3), using
the other tagged proteins mentioned previously as internal
controls. Both constructs displayed an export of mitoxantrone
from cells that was inhibited by fumitremorgin C (FTC), a specific
inhibitor of ABCG2 [37]. Although in these experiments the
inhibitory effect of FTC is modest in comparison to other studies
of ABCG2 isoforms [38], we have shown here that data obtained
with our YFP and half-YFP tagged constructs (Figure 3 C-E) is
similar to that of the wild type ABCG2 construct (Figure 3B),
supporting the conclusion that that the N-terminal tagging of
ABCG2 with half molecules of YFP does not negatively impact on
the function of the protein.
In contrast to the data shown in Figure 2 and 3, the tagging of
ABCG2 at the C-terminus with half molecules of YFP (or with full
length YFP) resulted in poor trafficking, increased intracellular
retention, and no convincing functional mitoxantrone export (data
not shown). Previously, the final few C-terminal residues of
ABCG2 have been shown to be sensitive to mutation (in terms of
protein trafficking [39]) and this further indicates that the C-
terminus contains the sequence motifs that are recognized by
cellular processing machinery.
Co-expression of ABCG2 bearing complementing halves
of venus YFP results in BiFC at the plasma membrane
Having compared the effects of N-terminal and C-terminal
tagging of ABCG2, only N-terminal tagged isoforms of ABCG2
were investigated for their ability to promote vYFP fragment
association and refolding. To validate BiFC we performed both
single transfections and co-transfections with vYN-ABCG2 and
vYC-ABCG2 (Figure 4). As expected, single transfections into
HEK293T cells did not result in the detection of a YFP fluorescent
signal (Figure 4A,B, middle and right hand panels), although protein
expression was confirmed in both cases (Figure 4A, left panel). The
co-transfection of both constructs resulted in protein expression at
the membrane as detected by 5D3 antibody (Figure 4C, left panel),
and in the formation of a fluorescence complementation signal
detectable by both flow cytometry and by fluorescence microscopy
(Figure 4C, middle and right panels). Time course experiments
revealed that this complementation could be observed as early as
16 hours post-transfection at 37uC, but that optimal signals were
obtained 36–48 hours post-transfection.
ABCG2 BiFC with other non-specific partner proteins
results in aggregations of BiFC complexes
The interaction of vYN and vYC to form a fluorescent complex
is essentially irreversible, as numerous hydrogen bonds are formed
during the association, and the strand arrangement of the YFP b-
barrel precludes a simple dissociation of the two fragments
[21,22,23]. Consequently, it is important in BiFC studies to
determine whether the driving force for complementation is the
interaction of the protein partners, or whether the vYN:vYC
interaction is the driving force [22,23,24,26]. To address this
issue we performed co-expression studies in which the cognate
Figure 3. N-terminal tagging with K YFP molecules does not
affect function of the ABCG2 protein. HEK293T cells were
transiently transfected with YFP_ABCG2 constructs (C-E) or negative
control (empty pcDNA vector; A) and positive control (His12-ABCG2) as
described in Methods and Materials. Following transfection aliquots of
cells were incubated with the ABCG2 substrate mitoxantrone in the
presence or absence of the inhibitor fumitremorgin C (FTC) and cellular
fluorescence determined by flow cytometry. Blue filled histograms
represent the cellular fluorescence in the absence of FTC, and the
rightward shift in the presence of the inhibitor (black lines)
demonstrates functional competence at a level similar to those of the
characterized control His12-ABCG2 (B). The apparent large number of
cells with zero fluorescence in the eYFP-ABCG2 panel (C) is a
fluorescence artefact due to interference from the YFP fluorescence
of this construct. The graphs are representative of .5 independent
experiments.
doi:10.1371/journal.pone.0025818.g003
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interaction of two ABCG2 proteins (i.e. vYN-ABCG2 and vYC-
ABCG2) was examined in parallel with co-transfections in which
vYN-ABCG2 was expressed together with a non-specific partner
protein, namely the b2 adrenergic receptor (b2-AR, [21]). Co-
expression of vYN-ABCG2 and vYC-ABCG2 resulted in a
fluorescence complementation signal that was at the cellular surface
(Figure 5B, middle and right hand panel), indicating that the BiFC
interaction did not detract from the effective trafficking of ABCG2.
Conversely, the interaction of vYN-ABCG2 and b2-AR-vYC
resulted in the observation of dense cytoplasmic fluorescence foci,
and the retention of ABCG2 within the cell (Figure 5C, middle and
right hand panel; this non-specific BiFC was also associated with
increased cell death). Thus, although there is evidence of a BiFC
interaction observed in these latter transfectants, the interaction of
ABCG2: b2AR is not conducive to efficient protein trafficking. This
type of observation has been made previously in studies of B cell
receptor oligomers [40], where specific protein:protein interactions
between partner proteins resulted in membrane localized BiFC,
whereas non-specific interactions resulted in cellular accumulation
of BiFC fluorescence.
Analysis of predicted ABCG2 dimer interface mutations
by BiFC
Understanding the dimer interface of ABCG2 is central to
understanding its mechanism. We investigated whether residues in
ABCG2, which are likely to participate in interactions between
two monomers in a dimer, could result in a change in the
dimerization reported by BiFC. Mutation of the conserved
Walker-B glutamate residues (in ABCG2 this corresponds to the
mutation E211Q) has been shown in numerous in vitro and
structural investigations of other ABC proteins to result in the
tighter apposition of the 2 NBDs with concomitant, irreversible
Figure 4. Complementation of YFP-ABCG2 constructs occurs at the plasma membrane. Constructs expressing half-tagged vYFP-ABCG2
individually (A, B) or together (C) were transfected into HEK293T cells as indicated schematically to the left. Constructs reached the plasma
membrane as confirmed by immuno-staining with 5D3 antibodies (left hand panel). No fluorescence could be detected at 515 nm by flow cytometry
of cells transfected with the vYN-ABCG2 or vYC-ABCG2 construct, but in co-transfected cells a YFP fluorescence was detected (middle panel).
Confirmation of the BiFC interaction was obtained from imaging fixed cells by fluorescence microscopy (right hand panel). DAPI was employed as a
nuclear counter-stain. Individual transfections resulted in only DAPI labelled nuclei in such experiments. Data are representative of at least 4
independent experiments.
doi:10.1371/journal.pone.0025818.g004
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trapping of the nucleotide substrate [41,42,43,44,45]. A second
mutation, C603A, was introduced to prevent the inter-dimer
disulphide bond that has been shown to be necessary for
homodimer formation on non-denaturing SDS-PAGE, but which
is not required for function [13,15].
We co-transfected ABCG2 wild type and mutant isoforms
tagged with N- and C-terminal fragments of vYFP (Figure 6A-D).
All three constructs (WT, E211Q and C603A) showed BiFC
(Figure 6B-D respectively) producing a fluorescence signal far in
excess of the background observed with a single transfection
(Figure 6A). The use of 96-well plate transfections and quantitative
image analysis software (see Methods) enabled us to determine two
parameters that could reflect altered dimerization between wild
type ABCG2 and mutant isoforms. Firstly, we determined the
percentage of cells with fluorescence above a background
threshold (Figure 6E). Although the percentage of cells showing
BiFC was greater for the E211Q mutant – which might be
expected to form a stronger dimer – this was not statistically
significant by ANOVA. Secondly, we quantified the mean
fluorescence intensity signal as a measure of the strength of the
BiFC interaction (Figure 6F). Again, analysis of several thousand
cells in several independent transfections showed that there was no
difference in the fluorescence intensity for either mutant ABCG2
isoform, compared to the wild type.
This data indicates that the initial association of the interacting
monomers – which is the event that BiFC ‘‘captures’’ - is not
sufficiently altered by either of the mutations we introduced to be
detected. For the Walker-B mutation, structural data on related
ABC proteins places the Walker-B glutamate residues within 8 A˚
of the opposite NBD [46], and it has been shown on several
occasions that the mutation of the conserved glutamate to
glutamine produces an NBD protein that in vitro is able to
associate into a stable dimeric state in the presence of ATP, which
occludes ATP (see references in [46]) It may be that in the current
experiments in intact cells this tight NBD dimerization is not
recapitulated. For cysteine-603, which is located in the extracel-
lular loop between TM5 and TM6, it is arguable that our data is
consistent with the hypothesis that the residue is not essential for
dimerization [13,15] [38].
It seems probable that our inability to detect changes in BiFC
signal with these two mutations reflects both a combination of the
irreversibility of BiFC following initial association, which has been
discussed previously [21,26], and the potentially minor alterations
to ABC2 dimer status that a single amino acid change on a large
protein:protein interaction surface would engender. Despite recent
improvements to the specificity of the BiFC interaction which may
reduce false positive interactions (e.g. [24,26]), the irreversibility is
still unaddressed, precluding us from being able to use BiFC to
further investigate the structural basis of ABCG2 homodimeriza-
tion, i.e. identifying individual residues at the dimer interface.
However, it remains possible that the effects of multiple mutations
to a predicted interfacial site could be detected by BiFC, e.g. the
surface of helix TM1 which contains a T402L/G406L/G410L
dimerization motif [17].
Bimolecular fluorescence complementation is a powerful
technique for the detection of protein:protein interactions which
may be homo- and/or hetero-dimeric in nature, including
previous studies of cuticular lipid ABCG-type transporters in
plants [47]. We have demonstrated here that a BiFC signal,
specific to homodimeric ABCG2 interaction at the plasma
Figure 5. ABCG2 bimolecular fluorescence complementation is specific. HEK293T cells were transfected with constructs expressing either
eYFP-ABCG2 (as a positive fluorescence control, A), complementing halves of vYFP tagged to ABCG2 (B) or with vYN-ABCG2 and a non-specific
interaction partner b2 adrenergic receptor (b2AR) with a C-terminal vYC fragment (C). Live cell imaging (left hand panel) shows that all three
transfections result in cellular fluorescence indicating the complementation of both the cognate (ABCG2:ABCG2) and non cognate (ABCG2: b2AR)
protein pairs. However, cells fixed and counter stained with DAPI (middle panel) show that the BiFC signal arising from ABCG2:ABCG2 interaction is
membrane localized, in contrast to the BiFC signal from the ABCG2: b2AR interaction which shows cytoplasmic retention. Immunofluorescence of
cells with anti ABCG2 antibodies (right panel) further demonstrates that the ABCG2: b2AR interaction results in intracellular retention of ABCG2. Data
are representative of at least 4 independent experiments.
doi:10.1371/journal.pone.0025818.g005
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membrane, was observed and, importantly, that tagging ABCG2
with molecular fragments of vYFP did not perturb function or
localization. Our work, and the recent demonstration that ABCG2
can also be studied by Fo¨rster resonance energy transfer (FRET;
[38]), should promote further studies to examine heteromeric
interactions of ABCG2, such as those with the regulatory PIM1
kinase [48], using these fluorescence technologies.
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